After infection or immunization, naive CD8 + T cells undergo burstlike clonal proliferation and differentiation to generate a population of effector cells reactive against pathogen-associated antigens. After resolution of infection, the majority of responding cells are eliminated, allowing brisk restoration of immune homeostasis. A fraction of cells escape this fate and persist as memory cells [1] [2] [3] [4] [5] [6] . The presence of greater numbers of antigen-specific memory cells enables more efficient pathogen clearance upon secondary infection. Thus, dynamic regulation of T cell differentiation, proliferation and survival is required to generate then curtail effector responses while maintaining a subset of pathogen-specific memory cells after withdrawal of antigen.
TCR signaling is critical to both initiation and diversification of CD8 + T cell responses. Strong or repeated TCR signaling drives progressive changes in gene expression that result in loss of lymphoid homing potential, acquisition of effector cell functions and, ultimately, terminal effector differentiation and apoptosis 7, 8 . Conversely, memory cells differentiate in response to weak antigen signals that are insufficient to drive full effector differentiation 1, 5, 9 . Consequently, memory cells manifest only a subset of transcriptional changes accompanying effector differentiation, and their intermediate state of differentiation enables them to remain functionally quiescent, survive and circulate among secondary lymphoid tissues, where they can be efficiently recruited into secondary responses [10] [11] [12] . TCR signaling not only has a role in diversification of CD8 + T cell responses but also induces functionally distinct outcomes within specific subpopulations of CD8 + T cells. TCR stimulation of naive cells predominantly results in proliferation and differentiation, stimulation of effector cells drives rapid induction of effector cytokines and cytotoxic molecules, and stimulation of terminally differentiated effector cells induces apoptosis 1, 8, 9 .
AP-1 family TFs have a central role in transducing TCR-driven effector programs. AP-1 TFs, including c-Jun, JunD and JunB; c-Fos, Fosb, Fosl1 and Fosl2; and BATF1, BATF2 and BATF3, contain basic leucine zipper (bZip) domains that enable them to form heterodimeric complexes at palindromic 12-O-tetradecanoylphorbol-13-acetate (TPA) response elements (TREs; 5′-TGA(C/G)TCA-3′) 13, 14 . Members of the Jun family of AP-1 TFs are phosphorylated in response to TCR signaling and recruited to TREs within the enhancers of multiple genes involved in effector differentiation, where they predominantly activate gene expression [15] [16] [17] [18] [19] [20] . We hypothesized that modulation of the availability of AP-1 sites to Jun TFs allows TCR-driven effector programs to be modulated in a stage-specific and contextual manner in CD8 + T cells, allowing for generation of transcriptionally intermediate memory cells.
BACH2 is a 92-kDa transcriptional repressor of the bZip TF family 21 . BACH2 promotes the differentiation of Foxp3 + regulatory T (T reg ) cells, and this function is required under homeostatic conditions A r t i c l e s to prevent lethal inflammation 22 . In B cells, BACH2 is critical for somatic hypermutation and class-switch recombination, and its absence leads to impaired generation of class-switched antibody responses 23, 24 . BACH2, like the AP-1 TFs, contains a bZip domain and binds to Maf recognition elements (MAREs), which embed a TRE sequence 21 . Silencing of Bach2 mRNA after activation of CD8 + T cells in vitro results in reduced cellular persistence 25 . These observations led us to explore whether BACH2 regulates CD8 + T cell differentiation in vivo by controlling access of AP-1 family TFs to the regulatory elements of TCR-induced genes.
RESULTS

BACH2 is required for CD8 + T cell memory
Defective generation of Foxp3 + T reg cells in Bach2 −/− mice results in unrestrained effector differentiation among conventional T cells 22 . To evaluate the cell-intrinsic function of BACH2 in CD8 + T cells, we reconstituted C57BL/6 mice with 1:1 mixtures of congenically distinct CD45.1 + wild-type (WT) and Thy-1.1 + Bach2 −/− mature lineage-depleted (Lin − ) bone marrow (BM) cells (Supplementary Fig. 1a ) and evaluated their CD8 + T cells. We observed low frequencies of both effector (CD62L − ) and central memory (CD62L + CD44 + ) cells within the Bach2 −/− compartment, suggesting a cell-intrinsic function of BACH2 in either the generation or maintenance of antigen-primed CD8 + T cell responses ( Supplementary Fig. 1b,c) . We therefore sought to test whether BACH2 controls responses to defined antigens. We used an acute viral infection model wherein recombinant vaccinia virus expressing chicken egg ovalbumin (VV-OVA) is recognized by minimal numbers of adoptively transferred TCR-transgenic CD8 + T cells specific for the OVA 257-264 epitope (OT-I cells). First, mice were reconstituted with mixtures of congenically distinct CD45.1 + WT and Thy-1.1 + Bach2 −/− OT-I transgenic BM cells, and naive CD44 − CD62L + OT-I cells of both genotypes were isolated from reconstituted mice. Naive WT and Bach2 −/− cells were cotransferred at a 1:1 ratio into recipient C57BL/6 mice ( Fig. 1a and Supplementary  Fig. 1d ), which were then infected with VV-OVA. Bach2 −/− CD8 + T cells showed impaired expansion and a near-complete failure to establish long-lived memory responses (Fig. 1b,c) . The reduced ratio of Bach2 −/− to WT cells in spleens of immunized mice was similar to that in the lungs and liver, but there was a further reduction in the frequency of Bach2 −/− cells in lymph nodes (Fig. 1d) . Thus, BACH2 is required for maintenance of CD8 + T cell responses after primary infection in vivo.
To test the function of BACH2 in mediating secondary protective immunity after primary infection, we infected mice with a recombinant strain of Listeria monocytogenes expressing the OVA 257-264 epitope (LM-OVA) 60 d after individual transfer of normalized numbers of naive WT or Bach2 −/− OT-I cells and primary infection with VV-OVA. Consistent with decreased maintenance of CD8 + T cell responses in the absence of BACH2, mice that had initially received Bach2 −/− OT-I cells showed significant impairment in their ability to clear LM-OVA compared with mice that had received WT cells (Fig. 1e) . We also asked whether BACH2 is required for secondary recall responses. We cotransferred 1:1 ratios of WT and Bach2 −/− central memory T (T CM ) cells (CD44 + CD62L + ) or effector memory (T EM ) cells (CD44 + CD62L − ) isolated at day 14 after primary infection into infection-naive recipients then infected these mice with VV-OVA. Notably, both Bach2 −/− T CM and T EM cells showed defective secondary response kinetics, although the defect was more pronounced in T CM than T EM cells (Fig. 1f,g ). Collectively, these findings indicate that BACH2 has a nonredundant cell-autonomous role in maintenance of primary and secondary CD8 + T cell responses in vivo and in 
BACH2 restrains terminal differentiation
Progressive acquisition of effector characteristics is accompanied by loss of lymphoid homing potential and reduction in cellular lifespan 1, 7, 11 . We asked whether defective maintenance and lymphoid homing of Bach2 −/− CD8 + T cells responding to viral infection are accompanied by changes in differentiation state. Among antigen-experienced CD8 + T cells, CD62L + central memory cells, CD62L − KLRG1 − effector cells and KLRG1 + terminally differentiated effector cells have been described 1 . We measured expression of CD62L and KLRG1 on adoptively transferred naive WT and Bach2 −/− OT-I CD8 + T cells after viral infection. We observed excessive induction of terminally differentiated KLRG1 + cells and near-complete loss of CD62L + T CM cells among surviving Bach2 −/− cells at late time points after infection ( Fig. 2a-d) . However, the decline in total CD8 + T cell numbers among Bach2 −/− cells resulted in a decrease in the absolute number of terminally differentiated effector cells (Supplementary Fig. 2a ) in addition to memory cells. Consistent with augmented effector differentiation of Bach2 −/− cells, we noted higher expression of the effector cytokine interferon-γ (IFN-γ) upon brief restimulation ex vivo (Fig. 2e) . Conversely, retroviral overexpression of BACH2 in OT-I CD8 + T cells prevented acquisition of terminally differentiated effector cell characteristics upon transfer into mice subsequently infected with VV-OVA, as indicated by increased expression of CD62L and lower expression of CD44 and KLRG1 (Fig. 2f) . Additionally, cells transduced with BACH2 expressed reduced amounts of IFN-γ and the effector cytokine tumor necrosis factor (TNF) (Fig. 2g) .
Terminal differentiation is associated with loss of memory precursor potential among effector cells 26 . Accordingly, we observed a loss of CD127 + KLRG1 − memory precursor effector cells (MPECs) and an increase in the frequency of CD127 − KLRG1 + short-lived effector cells (SLECs) among Bach2 −/− cells at day 7 after infection ( Fig. 3a) . We also noted a reduction in the frequency of CD127 + cells within the CD62L − KLRG1 − effector population that predominates at day 7 ( Supplementary Fig. 2b) . We did not, however, observe differences in CD43 or CD27 expression [27] [28] [29] (Supplementary Fig. 2c,d) . We also observed increased acquisition of effector cell characteristics after stimulation of Bach2 −/− CD8 + T cells in vitro, and this was antigen dependent (Supplementary Fig. 3a) , proliferation independent ( Supplementary  Fig. 3b ) and associated with high expression of lymphocyte activation markers CD25 and CD69 (Supplementary Fig. 3c ).
Terminal differentiation of CD8 + T cells is accompanied by induction of apoptosis 30, 31 . We measured rates of proliferation and apoptosis among WT and Bach2 −/− CD8 + T cells responding to viral infection. Whereas BACH2 was dispensable for sustaining early proliferation (Fig. 3b) , we observed substantially increased rates of apoptosis in Bach2 −/− cells at days 5, 7 and 10 after infection (Fig. 3c) , coinciding with their marked decrease in cell number. Defective survival was not attributable merely to induction of apoptosis at the naive cell stage, as we observed high rates of apoptosis in successive rounds of cell division after stimulation of Bach2 −/− naive CD8 + T cells in vitro (Supplementary Fig. 3d ). Fig. 3e ).
Corresponding to widespread differences in the phenotypes of WT and Bach2 −/− RNA sequencing (RNA-seq) of these cells isolated at day 7 after acute infection showed widespread differences in gene expression ( Supplementary Fig. 4a and Supplementary Table 1 ) and enrichment of transcripts associated with effector differentiation ( Supplementary Fig. 4b and Supplementary Table 2 ). Gene expression differences between WT and Bach2 −/− cells persisted but were substantially mitigated when fractionated populations of CD62L − KLRG1 − effector cells were specifically analyzed ( Supplementary Fig. 4c and Supplementary Table 3) . Thus, BACH2 restrains terminal effector differentiation and apoptosis, enabling generation of long-lived memory cells after viral infection.
BACH2 controls TCR-driven transcriptional programs AP-1 TFs bind to genomic TREs and have central roles in transducing TCR-driven effector programs. We hypothesized that BACH2 restrains TCR-driven terminal effector differentiation by binding to TREs and attenuating the activity of AP-1 factors. We mapped genome-wide BACH2 binding sites using chromatin immunoprecipitation (ChIP) coupled with massively parallel DNA sequencing (ChIP-seq). To generate sufficient numbers of cells for ChIP, we isolated naive CD8 + T cells by flow cytometry, cultured them with plate-bound anti-CD3 and anti-CD28 in the presence of IL-2 for 2 d then harvested them after an additional 3 d of culture (cells are referred to hereafter as d5 in vitro-activated CD8 + T cells). ChIP-seq of these cells showed extensive binding of BACH2 at intergenic and intronic regions (Fig. 4a) . Analysis of these sites enabled identification of a BACH2 consensus motif (5′-TGA(C/G)TCAGC-3′) in CD8 + T cells, in which was embedded the canonical AP-1 recognition motif (5′-TGA(C/G)TCA-3′) 34 (Fig. 4b) . Notably, this consensus motif was very similar to a BACH2 recognition motif resolved by PCR-assisted binding-site selection in vitro 21 . Given that a majority of BACH2 binding sites were outside annotated promoter regions, we next asked whether BACH2 binds to enhancers. We measured the genome-wide distribution of the coactivator protein p300 and histone H3 acetylation at K27 (H3K27ac) or monomethylation at K4 (H3K4me1), which are characteristically located at enhancers 35 . We found that a majority of BACH2 binding sites colocalized with one or more of these markers (Fig. 4c) . Consistent with similarity in BACH2 and AP-1 binding motifs, BACH2 binding sites were enriched at known genome-wide binding sites of AP-1 family members JunB, c-Jun and JunD 17 ( Fig. 
4d-f and Supplementary Tables 4-6).
The extensive colocalization of BACH2 at known AP-1 sites in CD8 + T cells suggests that BACH2 may function to limit TCR-driven gene expression in CD8 + T cells. A prediction of this hypothesis is that the majority of TCR-driven genes repressed by BACH2 will not be differentially expressed in Bach2 −/− and WT cells before stimulation. To test this, we measured global changes in gene expression induced by brief (6 or 18 h) ex vivo stimulation of naive CD44 − CD62L + WT and Bach2 −/− CD8 + T cells using RNA-seq. We identified 192 TCRdriven genes that were upregulated in Bach2 −/− cells at 0, 6 or 18 h after stimulation (fold change (FC) > 2; P < 0.05) (Fig. 5a) . Most of these genes (163, 84%) did not show significant differences in expression at 0 h (i.e., before stimulation) (Fig. 5b,c BACH2-mediated repression of TCR-driven gene expression is exemplified at the Ifng and Gp49a (Lilr4b) loci (Fig. 5e) , where we observed colocalization of BACH2 and AP-1 factors at known 36 
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A r t i c l e s in Bach2 −/− cells was driven by Jun factors, we used JNKi, a wellcharacterized pharmacological inhibitor of Jun N-terminal kinase (Jnk) 37 , which activates Jun family TFs in response to TCR signaling 38 . Pretreatment with JNKi partially reversed excessive induction of Gp49a and Ifng mRNA in naive Bach2 −/− cells after stimulation (Fig. 5f) . Moreover, BACH2-mediated repression of TCR-driven Gp49a and Ifng expression was abrogated in cells overexpressing BACH2 with a disrupted bZip domain (∆Zip BACH2), indicating that this suppression is dependent on the bZip domain (Fig. 5g) . Collectively, these results indicate that BACH2 restrains TCR-driven transcriptional programs associated with terminal effector differentiation in naive CD8 + T cells.
BACH2 limits access of Jun family TFs to its binding sites
We hypothesized that BACH2 represses TCR-driven gene expression by competing with AP-1 factors for DNA binding. A prediction of this hypothesis is that loss of BACH2 will lead to increased binding of Jun family TFs at BACH2 binding sites. BACH2 was expressed at readily detectable levels in WT d5 in vitro-activated CD8 + T cells ( Fig. 6a and Supplementary Fig. 5a ). We restimulated WT and Bach2 −/− in vitro-activated CD8 + T cells with plate-bound anti-CD3 for 2 h and subjected them to ChIP-seq analysis of JunD binding or RNAseq analysis. Notably, Bach2 −/− cells showed increased global binding of JunD at BACH2 binding sites compared with WT cells (Fig. 6a) despite having similar levels of total JunD (Fig. 6a) . This JunD enrichment was restricted to shared JunD-BACH2 binding sites, as average JunD binding was not significantly increased at JunD sites where BACH2 does not bind (Supplementary Fig. 5b ). Moreover, a proportion of JunD binding sites identified in Bach2 −/− cells was not detected in WT cells, indicating that BACH2 prevents JunD binding with extremely high efficiency at a subset of loci ( Supplementary  Fig. 5c,d and Supplementary Table 9 ). In contrast to increased JunD binding, we observed little difference in chromatin accessibility at BACH2 binding sites between WT and Bach2 −/− d5 in vitro-activated CD8 + T cells (Fig. 6b) . Similarly, we found no correlation between the differences in JunD binding observed at BACH2 binding sites and levels of chromatin accessibility in WT and Bach2 −/− cells (Supplementary Fig. 6a ). Thus, within in vitro-activated CD8 + T cells, BACH2 inhibits JunD binding without affecting chromatin accessibility. This behavior is consistent with a function of BACH2 as a passive transcriptional repressor 39 .
We next asked whether differences in JunD binding were associated with differences in gene expression. We compared average differences in JunD binding at BACH2 binding sites with differences in expression of associated genes in WT and Bach2 −/− d5 in vitro-activated CD8 + T cells. Increased JunD binding in Bach2 −/− cells was positively correlated with increased expression of associated genes, especially among TCR-induced genes (Fig. 6c,d and 
A r t i c l e s
Supplementary Table 10 ). We confirmed increased JunD binding by qPCR-based ChIP quantification at select loci and extended our analysis by measuring occupancy of JunB and c-Jun, in addition to JunD, at these sites (Supplementary Fig. 6b ). We observed increased JunD binding at all loci examined, increased c-Jun binding at a majority of loci and no increases in JunB binding in Bach2 −/− cells. Loss of BACH2 ChIP signals in Bach2 −/− cells confirmed specificity of the ChIP assay (Supplementary Fig. 6b ).
Because passive transcriptional repressors work through competition with transcriptional activators, they often share DNA-binding domains with the transcriptional activators they antagonize 39 . BACH2 and AP-1 TFs share DNA-binding bZip domains. Consistent with a requirement for the bZip domain in repression of TCR-induced genes, BACH2 inhibition of TCR-induced gene expression was abrogated in cells transduced with BACH2 ∆Zip (Fig. 6e) . Additionally, and similarly to our observations in naive cells, excessive induction of TCR-driven genes in Bach2 −/− d5 in vitro-activated cells was partially reversed upon pharmacological inhibition of Jun activity with JNKi (Fig. 6f) . This led us to ask whether maintenance of CD8 + T cell responses to acute infection is dependent on the BACH2 bZip domain. Retroviral overexpression of BACH2 partially rescued the secondary response of d5 in vitro-activated Bach2 −/− OT-I cells upon transfer and VV-OVA infection in vivo, whereas overexpression of ∆Zip BACH2 did not (Fig. 6g) . Collectively, these results indicate that BACH2 functions as a passive repressor of TCR-driven transcriptional programs, competing for access with AP-1 factors at a subset of its binding sites.
Stage-specific control of TCR-driven programs by BACH2
Given that effector differentiation proceeds in cells harboring intact Bach2 loci, we asked whether BACH2 expression is attenuated to permit effector differentiation in a subset of cells. Analyzing known genome-wide distributions of histone modifications in CD8 + T cells 40 , we noted decreased promoter-bound H3K4me3 at the Bach2 locus in memory and effector cells compared with naive cells (Fig. 7a,b) . Consistently, Bach2 mRNA expression was highest in naive OT-I CD8 + T cells and was progressively downregulated in central memory (CD62L + KLRG1 − ), effector (CD62L − KLRG1 − ) and terminally differentiated effector (CD62L − KLRG1 + ) cells 21 d after VV-OVA infection (Fig. 7c) . We observed corresponding changes in expression of Bach2 mRNA and the encoded protein in bulk populations of CD8 + T cells at serial time points after infection, with early decreased expression at days 5 and 7, when effector cells predominate, and increased expression at day 30, when memory cells recrudesce ( Supplementary  Fig. 7) . Thus, expression of Bach2 is dynamically regulated in CD8 + T cells at distinct stages of differentiation.
We asked whether modulation of Bach2 mRNA expression enables stage-specific control of its function. CD62L − KLRG1 − cells isolated at day 7 after infection (d7 Eff) expressed lower levels of Bach2 mRNA and the encoded protein than naive cells (Fig. 7d) . Both WT and Bach2 −/− d7 Eff cells are present in sufficient numbers for transcriptional analysis. We hypothesized that the effect of Bach2 deficiency on TCR-driven gene expression would be less substantial in d7 Eff cells than in naive cells, corresponding to its lower expression in these cells. We conducted RNA-seq analysis of TCR-induced gene expression in WT and Bach2 −/− naive and d7 Eff cells. We identified TCR-driven genes that were upregulated in naive Bach2 −/− cells compared with WT cells at 0 or 6 h after stimulation (Fig. 7e) . We then compared TCR-induced expression of these genes in WT and Bach2 −/− naive and d7 Eff cells (Fig. 7f,g and Supplementary Table 11) . Notably, most of the genes differentially expressed in naive cells were not significantly differentially expressed between WT and Bach2 −/− d7 Eff cells at 0 or 6 h after stimulation, corresponding with reduced BACH2 expression in this subset (Fig. 7f,g ). Thus, dynamic regulation of BACH2 expression enables stage-specific control of TCR-driven transcriptional programs.
Contextual control of BACH2 function by phosphorylation
Incomplete extinguishment of Bach2 mRNA expression in KLRG1 + terminally differentiated CD8 + T cells prompted us to explore whether BACH2's function is further regulated by post-translational modification. We noted decreased mobility of BACH2 upon denaturing gel electrophoresis of lysates from cells that were briefly restimulated with anti-CD3, which was reversed upon treatment with lambda phosphatase (Fig. 8a) . This suggested that BACH2 is A r t i c l e s phosphorylated upon TCR stimulation. A highly conserved serine residue (S520) of murine BACH2 corresponds to a previously reported phosphoresidue of human BACH2 in chronic myeloid leukemia cell lines 41 ( Fig. 8b) . The residues surrounding S520 form a consensus motif of the serine-threonine kinase Akt. To test whether BACH2 S520 is phosphorylated by Akt after TCR stimulation, we transduced CD8 + T cells with retroviruses encoding WT BACH2 or a substitution mutant BACH2(S520A) after primary stimulation in vitro. Four days after transduction, cells were restimulated by crosslinking of surfacebound anti-CD3 monoclonal antibodies. Using an Akt-substrate motif-specific antibody that detects RXXpS, we tested whether inhibition of Akt with a well-characterized and highly specific allosteric Akt inhibitor (AKTi) 42 prevents acute phosphorylation of BACH2 S520. Pharmacological inhibition of Akt prevented acute phosphorylation of BACH2, whereas inhibition of downstream mTORC1 activation with rapamycin did not (Fig. 8c) . Moreover, the S520A substitution prevented detectable phosphorylation. Thus, S520 phosphorylation of BACH2 after stimulation of CD8 + T cells is prevented by pharmacological inhibition of Akt. This observation led us to ask whether BACH2 is a direct substrate of Akt. We performed an in vitro kinase reaction combining purified Akt1 and BACH2 in the presence of ATP in vitro. Addition of purified Akt in the presence of ATP to BACH2 caused S520-dependent phosphorylation (Fig. 8d) , indicating that BACH2 S520 is a substrate of Akt kinase in vitro. Because Akt drives effector differentiation in CD8 + T cells [43] [44] [45] and effector differentiation is antagonized by its substrate BACH2, we hypothesized that phosphorylation of BACH2 promotes its functional inactivation, enabling effector differentiation to proceed. This hypothesis was supported by the observation that Akt inhibition suppresses effector differentiation in a partially BACH2-dependent manner (Supplementary Fig. 8 ). To test whether S520 phosphorylation functionally inactivates BACH2, we overexpressed BACH2 or BACH2(S520A) in CD8 + T cells stimulated in vitro in the presence of IL-2 and IL-12. Despite gating on cells expressing similar amounts of the transduction marker Thy-1.1, we noted enhanced suppression of effector cytokines and cell size when BACH2(S520A) was overexpressed (Fig. 8e) . We used strongly activating in vitro stimulation conditions, as overexpression of WT BACH2 caused near-complete suppression of effector cytokines among transferred cells after VV-OVA infection (Fig. 3b) , precluding assessment of a gain-of-function phenotype using this overexpression-based experimental system in vivo.
Phosphorylation of human BACH2 at a residue homologous to murine BACH2 S520 in chronic myeloid leukemia cells leads to its functional inactivation through nuclear exclusion 41 . To test whether phosphorylation of BACH2 causes its nuclear exclusion in T cells, we transduced CD8 + T cells with retroviral vectors expressing BACH2-GFP and BACH2(S520A)-GFP fusion proteins. The subcellular localization of GFP within transduced (Thy-1.1 + ) cells was resolved by imaging flow cytometry after brief restimulation to enable quantification of nuclear and cytoplasmic localization. WT BACH2 showed weaker GFP signal in the nucleus than BACH2(S520A) (Fig. 8f,g ), indicating that phosphorylation of BACH2 at S520 favors its nuclear exclusion in CD8 + T cells. Thus, S520 phosphorylation provides a mechanism for extrinsic modulation of BACH2 function and contextual control of CD8 + T cell differentiation.
DISCUSSION
Here we report a cell-autonomous role for BACH2 in regulating CD8 + T cell differentiation and function after primary and secondary infection in vivo. BACH2 restrains terminal effector differentiation and apoptosis within a subset of cells responding to viral infection, allowing generation of long-lived memory cells that mediate secondary protection upon pathogen reencounter. BACH2 binds to AP-1-like sites within enhancers and modulates their availability to Jun family signaldependent TFs. In less differentiated cells, this enables BACH2 to prevent TCR-driven induction of genes associated with terminal differentiation; in effector cells, reduction of Bach2 mRNA expression and phosphorylation of BACH2 protein permit TCR-driven induction of effector cell transcriptional programs. The observation that BACH2 modulates binding of Jun factors without affecting chromatin accessibility in activated CD8 + T cells suggests that BACH2 engages in passive transcriptional repression through competition with AP-1 factors for DNA binding. This is consistent with published observations that BACH2 exerts chromatin-independent repression of TPA-induced luciferase reporter gene expression driven by nonchromatinized MARE sequences 46 . These results do not exclude the possibility that BACH2 modulates chromatin structure in other cell types or CD8 + T cell subsets. The localized function of BACH2 in modulating access of AP-1 factors at enhancers is characteristic of short-range repression, which permits multiple enhancers to function autonomously within a promoter 47 ; this function is compatible with a requirement for complex regulation of genes involved in lymphocyte differentiation. IRF4 is known to assemble with AP-1 factors at AP-1-IRF composite elements 48 . We did not observe statistically significant differences in Irf4 mRNA expression between WT and Bach2 −/− cells. Because Irf4 is therefore unlikely to be a transcriptional target of BACH2 in CD8 + T cells, we conclude that differences in AP-1 factor binding in Bach2 −/− cells are not attributable to an IRF4-dependent mechanism. It is also notable that only a subset of TCR-induced gene loci contributed strongly to the correlation between differences in JunD binding and gene expression in WT and Bach2 −/− cells. These findings suggest that the extent of competition between BACH2 and AP-1 and its effect on gene expression may vary in a site-specific fashion. It will be important for future investigations to dissect the molecular mechanisms and sequence-level determinants of sitespecific regulation of BACH2 function.
We found that reduced transcription of Bach2 in effector cells corresponded to a decrease in its ability to restrain TCR-induced gene expression, enabling stage-dependent control of its function. BACH2 was also post-translationally modified to enable further contextual regulation of its function. Our finding that BACH2 phosphorylated at S520 is functionally inactivated are consistent with published observations in chronic myeloid leukemia cells that phosphorylation at a homologous residue in human BACH2 causes nuclear exclusion and functional inactivation 41 . Further investigations will be required to precisely quantify the effect of changes in BACH2 expression and nuclear exclusion on binding of BACH2 and AP-1 factors at enhancers. We used TCR stimulation to study BACH2 phosphorylation; however, the finding that BACH2 is phosphorylated by Akt provides a potential mechanism by which a variety of extrinsic cues modulate T cell differentiation. The PI3K-Akt pathway integrates diverse antigenic, inflammatory, costimulatory and metabolic signals and regulates multiple aspects of lymphocyte biology 44, 45, 49, 50 . It will be important to investigate the range of signals that regulate immune function via phosphorylation of BACH2 and how phosphorylation affects BACH2 function at endogenous levels of expression.
Collectively, our results show that BACH2 regulates transcriptional responses of CD8 + T cells to TCR signaling, enabling appropriate control of responses to viral infection. Our findings provide a basis for further investigation into how BACH2 controls the differentiation and function of CD8 + T cells and other lymphocyte lineages. Additionally, our results identify a new target for therapeutic manipulation of lymphocyte function in the context of chronic infection, autoimmunity and cancer.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Gene Expression Omnibus: Microarray data have been deposited under accession code GSE77857.
Illumina) according to the manufacturer's instructions. Sequenced reads were aligned to the mouse genome (NCBI37/mm9) with Tophat 2.0.11 (ref. 51) , and uniquely mapped reads were used to calculate gene expression. RefSeq gene database (mm9) was downloaded from the UCSC genome browser for RNA-seq analysis. Raw counts that fell on exons of each gene were calculated, and differentially expressed genes were identified with the statistical R package edgeR 52 or Cuffdiff 53 . Fisher's exact test or t-test were used to evaluate significance with indicated P value and fold-change thresholds. Expression heat maps were generated with the R package pheatmap.
Chromatin immunoprecipitation and accessibility assays. T cells were chemically crosslinked and sonicated to generate fragmented genomic DNA. Chromatin immunoprecipitation was performed using the following antibodies: anti-BACH2 (N-2; Tohoku University), anti-JunD (sc-74), anti-c-Jun (sc-45), anti-JunB (sc-73) and anti-p300 (sc-586; Santa Cruz) anti-H3K4me1 (ab8895) and anti-H3K27Ac (ab4729; Abcam). For PCR-based confirmation of BACH2 binding, chromatin immunoprecipitation was performed as described above, and qPCR reactions were carried out on input and immunoprecipitated DNA using the Power SYBR Green kit (Applied Biosystems). Genomewide measurement of chromatin accessibility and computational alignment of generated data were performed using ATAC-Seq on 50,000 d5 in vitroactivated CD8 + T cells as described 54 . Subsequent bioinformatic analyses were performed as described below.
ChIP-seq analysis. For sequencing of immunoprecipitated DNA, DNA fragments were blunt-end ligated to Illumina adaptors, amplified, and sequenced by using the HiSeq 2000 platform (Illumina). Sequenced reads of 50-125 bp were obtained by using the Illumina Pipeline. Sequenced reads were aligned to the mouse genome (NCBI37/mm9) with Bowtie 0.12.9 (ref. 55); only uniquely mapped reads were retained. The output of Bowtie was converted to BAM files, which represent the genomic coordinates of each read. Reads were mapped into nonoverlapping 10-bp windows, and the location of reads on positive (negative) strand was shifted ±75 bp from its 5′ start to determine the approximate center of the DNA fragment associated with the reads. Genomic graphs were generated and viewed using the IGV (Integrative Genomics Viewer) 56 , and we aligned the BACH2, JunD, cJun, p300, H3K4me1, H3K27ac and input control in CD8 + T cells.
Peak calling, motif discovery and genome-wide distribution analysis. We used MACS 1.4.2 (ref. 57) to call binding sites (peaks) relative to input control libraries. The binomial distribution test was used to assess peak significance, and a P value threshold of 1 × 10 −5 was used unless otherwise specified. For motif discovery, the most significant 1,000 peaks ranked by lowest P value were used, and 100-bp DNA sequences centered on each peak summit were analyzed using MEME to characterize the BACH2 consensus binding motif in mouse CD8 + T cells. The discovered motifs were compared with the JASPAR motif database to evaluate motif similarities. 5′ untranslated regions (UTRs), 3′ UTRs, introns, exons and intergenic regions were defined according to the RefSeq database. Peaks were identified to be associated with genes if they were found between 15 kb upstream of the transcription start site and 3 kb downstream of the transcription end site of that gene. The distance between summits of two peaks was calculated and plotted as histograms using the R package.
Genome-wide binding profiles. Genome-wide binding profiles were established by counting the reads into binned windows (20 bp/bin) relative to peak summits. Normalized read densities were plotted in the range [−1 kb, 1 kb] centered on peak summits. The Kolmogorov-Smirnov test was used to evaluate the significance between different distributions.
Statistical testing. Unless otherwise specified, statistical tests were performed using unpaired two-tailed Student's t-test. Where necessary, the Shapiro-Wilk test was used to test for normality of the underlying sample distribution. No blinding was done, as objective quantitative assays such as flow cytometry, were used. Experimental sample sizes were chosen using power calculations with preliminary experiments or were based on previous experience of variability in similar experiments. Samples that had undergone technical failure during processing were excluded from analyses. Where relevant, recipient mice were randomized before adoptive transfer.
